Hotgen Biotech: Subsidiary innovative drug SGC001 injection added indications clinical trial application accepted.

Recon Biotechnology announced that its holding subsidiary Shunjing Pharmaceutical's independently developed innovative drug SGC001 injection has received approval for clinical trial application for the new indication of severe acute pancreatitis from the National Medical Products Administration's issued "Acceptance Notice". SGC001 is an emergency monoclonal antibody drug jointly developed by Shunjing Pharmaceutical's research team and the Beijing Institute of Cardiovascular Diseases of Capital Medical University, suitable for emergency treatment of patients with acute myocardial infarction. Previously, there were no related antibody drugs entering clinical research and approval for listing for AMI disease.